

IMIPENEM-CILASTATIN

BRAND NAME PRIMAXIN

DRUG CLASS Carbapenem antibiotic

AVAILABILITY Vial contains 500 mg of imipenem and 500 mg of cilastatin as cilastatin sodium.

Also contains sodium bicarbonate. Contains 1.6 mmol of sodium.¹

This is a carbapenem (beta-lactam antibiotic). If the patient has a history of hypersensitivity to penicillins **and** cephalosporins, or carbapenems, check with the treating team that allergy status has been considered.

рΗ 6.5-8.5 when reconstituted1

PRFPARATION A two-step process is required because imipenem is poorly soluble.

> To prepare a dose of 500 mg (of imipenem): use 2 syringes to withdraw 10 mL each from a 100 mL bag of a compatible fluid. Use the first syringe of 10 mL to reconstitute the vial. Shake well, it is a suspension (not a solution). Immediately withdraw the contents of the vial and transfer to the remaining fluid in the 100 mL infusion bag. Use the second syringe of 10 mL to rinse the vial. Shake well and immediately withdraw and transfer the contents to the infusion bag. Shake the bag well until a

The final concentration is approximately 5 mg/mL (of imipenem).²

For doses of more than 500 mg (of imipenem) use a larger volume bag of infusion fluid (e.g. 1 g (of imipenem) in 250 mL) and repeat the two-step process to prepare each vial of imipenem-cilastatin.

Concentrations of 2.5-5 mg/mL (of imipenem) have been used.3

Powder volume is not required. The product information provides advice for doses less than 500 mg (of imipenem).⁴ It is not recommended to take a part-dose from a suspension.

The solution is colourless to yellow.1

clear solution is formed.1

STABILITY Vial: store below 25 °C.1

Reconstituted suspension: dilute immediately.1

Infusion solution: use immediately. Stable for 4 hours below 25 °C or for 24 hours at

2 to 8 °C.1,3

ADMINISTRATION

IM injection Not recommended¹ SUBCUT injection Not recommended IV injection Not recommended

IV infusion See PREPARATION. For doses up to 500 mg (of imipenem) infuse over 20 to

30 minutes. For doses up to 1 g (of imipenem) infuse over 40 to 60 minutes.¹

IV use for infants See PREPARATION. Dilute the dose to a concentration of 5 mg/mL (of imipenem). and children

Infuse doses up to 500 mg (of imipenem) over 20 to 30 minutes and doses up to 1 g

(of imipenem) over 40 to 60 minutes.^{5,6}

COMPATIBILITY

Fluids Sodium chloride 0.9%¹, glucose 5%¹, glucose in sodium chloride solutions¹, Plasma-

Lyte 148 via Y-site7

Y-site Aciclovir³, amifostine³, anidulafungin³, caspofungin³, defibrotide³, foscarnet³,

granisetron³, isavuconazole³, linezolid³, meropenem³, remifentanil³, tigecycline³,

zidovudine³

INCOMPATIBILITY

Fluids Hartmann's^{1,3}, mannitol 15%⁸

Drugs Amiodarone³, amoxicillin³, azathioprine⁸, azithromycin³, ceftriaxone⁸, daptomycin⁸,

ganciclovir⁸, haloperidol lactate⁸, lorazepam³, mannitol 15%⁸, metaraminol⁸, midazolam³, milrinone³, mycophenolate mofetil8, nicardipine8, palonosetron8,

pethidine³, pyridoxine⁸, sodium bicarbonate³, thiamine⁸, vecuronium⁸

SPECIAL NOTES Slow the rate of infusion if the patient develops nausea or vomiting.¹

REFERENCES

Product information. Available from www.tga.gov.au. Accessed 14/11/2023.
Primaxin IV 500mg/500mg powder for infusion solution. Summary of product characteristics. London: Merck Sharp & Dohme (UK). Approved 30/06/1998. Updated 29/01/2021. Available from www.medicines.org.uk. Accessed 14/11/2023.
ASHP Injectable drug information 2021. Bethesda, MD: American Society of Health-System Pharmacists; 2021.
Medical information. Request AUU22-01926. [email]. Macquarie Park, NSW: Merck Sharp & Dohme Australia; 26/09/2022.
Paediatric Formulary Committee. BNF for children. London: BMJ group and Pharmaceutical Press; 2022–2023.
Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. Pediatric injectable drugs. The teddy bear book. 11th ed. Bethesda, MD: American Society of Health-System Pharmacists: 2018

Health-System Pharmacists; 2018.

Medical information. Plasma-Lyte 148 compatibility summary. Toongabbie, NSW: Baxter, March 2022.
Imipenem/cilastatin sodium. In: IV Index [internet]. Trissel's 2 clinical pharmaceutics database (parenteral compatibility). Ann Arbour, MI: Merative. Accessed 14/11/2023.

VERSION